QIAGEN N.V.
- Headquarters
- Netherlands
- Founded
- Not recorded
- Sector
- Life Sciences Tools
About QIAGEN N.V.
QIAGEN N.V. is a Netherlands-based holding company providing sample preparation, molecular testing, automation and bioinformatics products through its subsidiaries. Its technologies extract and analyze DNA, RNA and proteins from biological samples. The group serves life-sciences research, pharmaceutical development, industrial applications including forensics, and clinical molecular diagnostics.
Recorded address: Hulsterweg 82, 5912 PL Venlo, The Netherlands
- Reported manager AUM ↘
- Financial data requires access
- Investment strategies ↘
- 0Published strategy labels, not capital percentages
- Managed funds ↘
- 0Published fund records on DataBane
- Published relationships ↘
- 311 recorded transactions · 8 published people
Relationship intelligence
Open full relationship explorer →Relationship explorer
3 of 3 published relationships
Portfolio companies
Open portfolio explorer →Recorded investments and ownership events retain their lifecycle classification.
No qualifying public portfolio records are available. This is a coverage gap, not a statement that the firm has no investments.
Financial history & reporting
Reported AUM history
Geographic investment focus
Recorded mandates by country or region. Shading does not imply a holding in every country.
No geographic mandate is recorded.
Strategy coverage heatmap
Filled cells mark recorded strategy–asset-class associations. They do not measure capital, conviction or performance.
No strategy labels are recorded.
Deals
Browse all deals →QIAGEN and EQT XI announced a proposed all-cash takeover by Crown NL Bidco B.V., indirectly controlled by EQT XI. Luxinva S.A., wholly owned by ADIA, and CPP Investment Board Europe Inc., wholly owned by CPP Investments, hold indirect participations in the bidder. Closing was expected in mid-2027, subject to shareholder acceptance and regulatory conditions. No completed acquisition is asserted.
Team & contacts
Risk developments & research coverage
Published regulatory and risk news, alongside the reporting gaps that matter when interpreting this profile.
Regulatory & risk news
No dated, source-backed regulatory or risk development is currently recorded. This is a coverage gap, not a conclusion that the firm has no risks.
News classifications reflect published records. DataBane does not assign an investment-risk score from missing data.
Reporting status
- Last profile review
- 11/11/2026
QIAGEN N.V. — News
Jonathan M. Pratt joins QIAGEN Managing Board
QIAGEN announced shareholder approval of Jonathan M. Pratt as Managing Director and member of its Managing Board. Pratt became CEO on September 1, 2026 and joins CFO Roland Sackers on the board. Thierry Bernard stepped down as CEO and Managing Board member on September 1.
QIAGEN releases full third-quarter 2026 results
QIAGEN released its full third-quarter results and stated that its 2026 financial outlook remained suspended while the proposed EQT Private Equity transaction was pending. The release reported year-on-year sales growth and distinguished reported results from adjusted earnings measures.
QIAGEN announces proposed EQT XI-led takeover
QIAGEN and EQT XI announced a proposed all-cash takeover by Crown NL Bidco B.V. The bidder is indirectly controlled by EQT XI, with indirect participation by ADIA subsidiary Luxinva S.A. and CPP Investment Board Europe Inc. Closing was expected in mid-2027, subject to acceptance and regulatory conditions.
QIAGEN and Hamburg Trading commence Philippine distribution partnership
QIAGEN announced a life-sciences distribution partnership with Hamburg Trading Corporation and a QIAGEN Experience Lab in the Philippines. The lab supports demonstrations and training for molecular workflows. The webpage is dated July 6, 2026, while the release body carries a July 7 dateline.
Data quality & methodology
Coverage measures field presence, not accuracy. Financial verification, reporting freshness and profile review are separate checks. Read the methodology.
Last profile review
11/11/2026A profile review date is not the reporting date of an individual financial observation.
Network metrics and matching methodology
Network connectivity
13 / 1002 relationships across 1 types · entropy 0.00 bits
Recorded network strength
1 / 100Weighted 2 — 2 take private (×1)
These measures describe DataBane records. They are not investment performance, sentiment or credit-risk scores.
Additional company research context
- Investment style
- Not classifiedno asset classes tagged yet
- Diversification
- Not classifiedno asset classes or strategies tagged yet
- Geographic bias
- Not recordedno investment regions recorded
- Relationship coverage
- 3 recordsPublished, valid relationships with published counterparties
- Relationship history
- 2025-12-02Earliest recorded start; 3 of 3 relationships have valid start dates
- Firm age
- Not disclosedfounding year not available